AU2002363296A1 - Human secreted proteins - Google Patents

Human secreted proteins

Info

Publication number: AU2002363296A1
Authority: AU; Australia
Prior art keywords: secreted proteins; human secreted; human; proteins; secreted
Prior art date: 2001-03-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002363296A

Inventor

Craig A. Rosen

Steven M. Ruben

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-21

Filing date

2002-03-19

Publication date

2003-05-12

2002-03-19 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2003-05-12 Publication of AU2002363296A1 publication Critical patent/AU2002363296A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AU2002363296A 2001-03-21 2002-03-19 Human secreted proteins Abandoned AU2002363296A1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US27734001P	2001-03-21	2001-03-21
US60/277,340		2001-03-21
US30617101P	2001-07-19	2001-07-19
US60/306,171		2001-07-19
US33128701P	2001-11-13	2001-11-13
US60/331,287		2001-11-13
PCT/US2002/008277 WO2003038063A2 (en)	2001-03-21	2002-03-19	Human secreted proteins

Publications (1)

Publication Number	Publication Date
AU2002363296A1 true AU2002363296A1 (en)	2003-05-12

Family

ID=27402891

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
AU2002363296A Abandoned AU2002363296A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002320013A Abandoned AU2002320013A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002326293A Abandoned AU2002326293A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002324424A Abandoned AU2002324424A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002354719A Abandoned AU2002354719A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002332391A Abandoned AU2002332391A1 (en)	2001-03-21	2002-03-19	Human secreted proteins

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
AU2002320013A Abandoned AU2002320013A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002326293A Abandoned AU2002326293A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002324424A Abandoned AU2002324424A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002354719A Abandoned AU2002354719A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002332391A Abandoned AU2002332391A1 (en)	2001-03-21	2002-03-19	Human secreted proteins

Country Status (4)

Country	Link
EP (7)	EP1404702A4 (en)
AU (6)	AU2002363296A1 (en)
CA (7)	CA2441416A1 (en)
WO (7)	WO2002102993A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7196164B2 (en)	1997-07-08	2007-03-27	Human Genome Sciences, Inc.	Secreted protein HHTLF25
EP1000084A4 (en)	1997-07-08	2003-03-26	Human Genome Sciences Inc	123 human secreted proteins
EP2080802B1 (en)	1998-06-01	2017-03-29	Agensys, Inc.	Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en)	2000-12-06	2003-08-07	Hubert Rene S.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en)	1998-06-01	2004-07-22	Raitano Arthur B.	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en)	1999-06-01	2004-12-21	Agensys, Inc.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en)	2002-04-05	2006-03-09	Raitano Arthur B	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
CN1387538A (en)	1999-01-15	2002-12-25	比奥根公司	Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
EP1666490A3 (en) *	2000-07-25	2006-11-02	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7291719B2 (en)	2000-07-25	2007-11-06	Genentech, Inc.	PRO4332 antibodies
JP2004528823A (en)	2000-10-31	2004-09-24	ディアデクサスインコーポレーテッド	Compositions and methods for colon-specific genes and proteins
US20020111302A1 (en) *	2000-11-30	2002-08-15	Y. Tom Tang	Novel nucleic acids and polypeptides
US7736654B2 (en) *	2001-04-10	2010-06-15	Agensys, Inc.	Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7164007B2 (en)	2001-06-20	2007-01-16	Genentech, Inc.	Anti-PR020044 antibodies
US7494646B2 (en)	2001-09-06	2009-02-24	Agensys, Inc.	Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2537074T3 (en)	2001-09-06	2015-06-02	Agensys, Inc.	Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
EP1439235A4 (en)	2001-10-12	2006-01-18	Astellas Pharma Inc	Method of screening cell death inhibitor
KR101174214B1 (en)	2002-04-09	2012-08-14	바이오겐 아이덱 엠에이 인코포레이티드	Methods for treating tweak-related conditions
AU2003900747A0 (en) *	2003-02-18	2003-03-06	Garvan Institute Of Medical Research	Diagnosis and treatment of pancreatic cancer
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en)	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) *	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
EP1670947B1 (en)	2003-09-23	2015-04-01	University Of North Carolina At Chapel Hill	Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage
ATE466074T1 (en) *	2003-10-14	2010-05-15	Baxter Int	VKORC1 (VITAMIN K EPOXIDE RECYCLING POLYPEPTIDE), A THERAPEUTIC TARGET FOR COUMARIN AND THEIR DERIVATIVES
WO2005076003A2 (en) *	2004-02-03	2005-08-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en)	2004-02-20	2005-08-25	Yixin Wang	Breast cancer prognostics
AU2004319915B9 (en)	2004-04-22	2011-12-22	Agensys, Inc.	Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US8759305B2 (en)	2004-09-01	2014-06-24	Dynavax Technologies Corporation	Methods and compositions for inhibition of innate immune responses and autoimmunity
EP2093297A3 (en) *	2004-09-07	2009-11-18	Telethon Institute for Child Health Research	Agents for treatment or prevention of an allergic disorder
WO2006026808A1 (en) *	2004-09-07	2006-03-16	Telethon Institute For Child Health Research	Method of diagnosing and/or predicting the development of an allergic disorder
EP1859277A4 (en)	2005-02-17	2010-03-17	Biogen Idec Inc	Treating neurological disorders
CA2599284A1 (en)	2005-02-28	2006-08-31	Baxter International Inc.	Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression
EP1861499A4 (en)	2005-03-15	2008-09-03	Univ North Carolina	Methods and compositions for producing active vitamin k-dependent proteins
ES2432564T3 (en)	2005-05-10	2013-12-04	Biogen Idec Ma Inc.	Treatment and evaluation of inflammatory disorders
WO2006138219A2 (en)	2005-06-13	2006-12-28	Biogen Idec Ma Inc.	Methods of diagnosis / prognosis of inflammatory conditions
GB2470843B (en) *	2005-09-01	2011-04-13	Florey Howard Inst	Models and methods for the assessment of potential therapeutic agents for the modulation of NDFIP1-NEDD4 interactions
GB0521488D0 (en) *	2005-10-21	2005-11-30	Ares Trading Sa	Integral membrane protein
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
KR20140116546A (en)	2006-10-27	2014-10-02	제넨테크, 인크.	Antibodies and immunoconjugates and uses therefor
EP2083861A4 (en)	2006-11-07	2010-11-24	Merck Sharp & Dohme	Antagonists of pcsk9
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
EP2142217B1 (en) *	2007-03-27	2014-11-05	Merck Sharp & Dohme Corp.	Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en)	2007-08-23	2023-03-28	Amgen Inc	Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
CA2703931C (en)	2007-10-26	2016-08-16	Dynavax Technologies Corporation	Methods and compositions for inhibition of immune responses and autoimmunity
EP2215268B1 (en) *	2007-11-30	2018-08-29	Siemens Healthcare Diagnostics Inc.	Adiponectin receptor fragments and methods of use
AR070315A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
US8748115B2 (en)	2008-12-12	2014-06-10	Merck Sharp & Dohme Corp.	PCSK9 immunoassay
EP2493507A4 (en)	2009-10-30	2013-11-20	Merck Sharp & Dohme	Ax213 and ax132 pcsk9 antagonists and variants
WO2011053759A1 (en)	2009-10-30	2011-05-05	Merck Sharp & Dohme Corp.	Ax1 and ax189 pcsk9 antagonists and variants
KR101810593B1 (en)	2010-06-16	2017-12-22	다이나박스 테크놀로지 코퍼레이션	Methods of treatment using tlr7 and/or tlr9 inhibitors
PE20171640A1 (en)	2010-09-22	2017-11-09	Alios Biopharma Inc	REPLACED NUCLEOTIDE ANALOGS
US9631002B2 (en)	2010-12-21	2017-04-25	The University Of North Carolina At Chapel Hill	Methods and compositions for producing active vitamin K-dependent proteins
CA2860234A1 (en)	2011-12-22	2013-06-27	Alios Biopharma, Inc.	Substituted phosphorothioate nucleotide analogs
NZ631601A (en)	2012-03-21	2016-06-24	Alios Biopharma Inc	Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en)	2012-03-22	2015-04-21	Alios Biopharma, Inc.	Pharmaceutical combinations comprising a thionucleotide analog
US8883157B1 (en)	2013-12-17	2014-11-11	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9051378B1 (en)	2014-07-15	2015-06-09	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en)	2014-07-15	2015-02-03	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en)	2014-07-15	2015-05-19	Kymab Limited	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en)	2014-07-15	2015-05-05	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en)	2013-12-23	2017-06-20	Carefusion 2200, Inc.	Pleurodesis device and method
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
US9150660B1 (en)	2014-07-15	2015-10-06	Kymab Limited	Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR102569848B1 (en)	2016-12-23	2023-08-25	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	Gene editing of PCSK9
KR102667951B1 (en)	2017-04-03	2024-05-22	에프. 호프만-라 로슈 아게	Antibodies binding to STEAP-1
ES2963042T3 (en)	2017-06-22	2024-03-25	Procter & Gamble	Films that include a water-soluble layer and an organic vapor-deposited coating
CN110719968A (en)	2017-06-22	2020-01-21	宝洁公司	Film comprising a water-soluble layer and a vapor-deposited inorganic coating
WO2021207710A2 (en)	2020-04-09	2021-10-14	Verve Therapeutics, Inc.	Base editing of angptl3 and methods of using same for treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100236393B1 (en) *	1996-02-02	1999-12-15	나까니시 히로유끼	A pharmaceutical preparation containing a human growth hormone
WO2002026931A2 (en) *	2000-09-25	2002-04-04	Human Genome Sciences, Inc.	71 human secreted proteins
WO2000004140A1 (en) *	1998-07-15	2000-01-27	Human Genome Sciences, Inc.	71 human secreted proteins
US5858716A (en) *	1997-05-30	1999-01-12	Smithkline Beecham Corporation	H2CAA71 polynucleotides

2002
- 2002-03-19 AU AU2002363296A patent/AU2002363296A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008123 patent/WO2002102993A2/en not_active Application Discontinuation
- 2002-03-19 CA CA002441416A patent/CA2441416A1/en not_active Abandoned
- 2002-03-19 EP EP02759068A patent/EP1404702A4/en not_active Withdrawn
- 2002-03-19 EP EP02780789A patent/EP1423134A2/en not_active Withdrawn
- 2002-03-19 CA CA002441840A patent/CA2441840A1/en not_active Abandoned
- 2002-03-19 EP EP02799146A patent/EP1390390A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/009785 patent/WO2002095010A2/en not_active Application Discontinuation
- 2002-03-19 WO PCT/US2002/008124 patent/WO2003004622A2/en not_active Application Discontinuation
- 2002-03-19 AU AU2002320013A patent/AU2002320013A1/en not_active Abandoned
- 2002-03-19 CA CA002441397A patent/CA2441397A1/en not_active Abandoned
- 2002-03-19 CA CA002441755A patent/CA2441755A1/en not_active Abandoned
- 2002-03-19 EP EP02749512A patent/EP1381622A2/en not_active Withdrawn
- 2002-03-19 EP EP02782476A patent/EP1414845A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008276 patent/WO2002076488A1/en not_active Application Discontinuation
- 2002-03-19 AU AU2002326293A patent/AU2002326293A1/en not_active Abandoned
- 2002-03-19 AU AU2002324424A patent/AU2002324424A1/en not_active Abandoned
- 2002-03-19 CA CA002441832A patent/CA2441832A1/en not_active Abandoned
- 2002-03-19 EP EP02760994A patent/EP1379132A4/en not_active Withdrawn
- 2002-03-19 CA CA002441417A patent/CA2441417A1/en not_active Abandoned
- 2002-03-19 CA CA002441702A patent/CA2441702A1/en not_active Abandoned
- 2002-03-19 AU AU2002354719A patent/AU2002354719A1/en not_active Abandoned
- 2002-03-19 AU AU2002332391A patent/AU2002332391A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008279 patent/WO2002090526A2/en not_active Application Discontinuation
- 2002-03-19 EP EP02723499A patent/EP1379264A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008277 patent/WO2003038063A2/en not_active Application Discontinuation
- 2002-03-19 WO PCT/US2002/008278 patent/WO2002102994A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2441416A1 (en)	2003-01-16
WO2002095010A3 (en)	2004-02-12
WO2002102993A3 (en)	2004-03-25
AU2002326293A1 (en)	2003-01-02
CA2441397A1 (en)	2002-10-03
CA2441755A1 (en)	2003-05-08
CA2441702A1 (en)	2002-12-27
EP1414845A4 (en)	2009-07-08
EP1414845A2 (en)	2004-05-06
EP1381622A2 (en)	2004-01-21
WO2003004622A2 (en)	2003-01-16
EP1423134A2 (en)	2004-06-02
WO2003038063A2 (en)	2003-05-08
AU2002332391A1 (en)	2003-01-02
EP1390390A4 (en)	2009-07-08
WO2002102994A2 (en)	2002-12-27
EP1390390A2 (en)	2004-02-25
WO2002090526A3 (en)	2003-10-30
EP1379264A4 (en)	2009-07-08
AU2002320013A1 (en)	2002-11-18
EP1404702A2 (en)	2004-04-07
WO2002090526A2 (en)	2002-11-14
EP1379132A4 (en)	2009-07-01
EP1379132A2 (en)	2004-01-14
CA2441840A1 (en)	2002-11-28
EP1379264A1 (en)	2004-01-14
CA2441832A1 (en)	2002-12-27
WO2002095010A2 (en)	2002-11-28
WO2002102994A3 (en)	2003-07-24
WO2003004622A3 (en)	2004-02-19
WO2002102993A2 (en)	2002-12-27
AU2002354719A1 (en)	2003-01-21
AU2002324424A1 (en)	2002-12-03
EP1404702A4 (en)	2009-07-08
WO2002076488A1 (en)	2002-10-03
CA2441417A1 (en)	2002-11-14
WO2003038063A3 (en)	2003-12-11

Publication	Publication Date	Title
AU2002363296A1 (en)	2003-05-12	Human secreted proteins
AU2002321999A1 (en)	2002-12-16	Human secreted proteins
AU2002361452A1 (en)	2003-07-09	Secreted proteins
AU2002232596A1 (en)	2002-06-24	Secreted human proteins
AU2002353227A1 (en)	2003-07-15	Secreted proteins
AU2002342010A1 (en)	2003-04-14	Secreted proteins
AU2002354803A1 (en)	2003-01-21	Secreted proteins
AU2003301843A1 (en)	2004-06-07	157 human secreted proteins
AU2002255733A1 (en)	2002-09-19	Secreted proteins
AU2002252700A1 (en)	2002-11-05	Secreted proteins
AU2001294719A1 (en)	2002-04-08	Secreted human proteins
AU2002327533A1 (en)	2003-03-03	Secreted proteins
AU2002258657A1 (en)	2002-10-15	Secreted proteins
AU2002365153A1 (en)	2003-06-30	41 human secreted proteins
AU2002327176A1 (en)	2002-12-16	20 human secreted proteins
AU2002246998A1 (en)	2002-07-30	50 human secreted proteins
AU2002348034A1 (en)	2003-05-12	16 human secreted proteins
AU2002254275A1 (en)	2002-10-08	Human secreted proteins
AU2003211137A1 (en)	2003-09-09	20 human secreted proteins
AU2002257630A1 (en)	2002-09-24	Human mrp5-like protein
AU2002247189A1 (en)	2002-09-12	70 human secreted proteins
AU2002253985A1 (en)	2002-09-12	83 human secreted proteins
AU2002332483A1 (en)	2003-02-24	13 human secreted proteins
AU2002247042A1 (en)	2002-08-19	Secreted proteins
AU2002352912A1 (en)	2003-06-10	Secreted proteins

Legal Events

Date	Code	Title	Description
2004-02-19	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase